Literature DB >> 1832810

Immune imbalance in the synovial fluid of rheumatoid arthritis patients: effects of intra-articular injection of thymopentin.

A Afeltra1, M Galeazzi, P Basso, A Pietrucci, O De Pità, G M Ferri, F Porzio, L Bonomo.   

Abstract

T cell subsets in the synovial fluid (SF) and peripheral blood (PB) of RA patients and controls suffering from different forms of chronic synovitis have been investigated. The immunological evaluation showed a reduction of CD4 subsets in RA-SF compared to RA-PB (p less than 0.001), and an almost complete absence of the suppressor-inducer/naive T cells in RA-SF compared to RA-PB and SF from patients with other forms of chronic synovitis. The CD8 subpopulation showed an increased proportion of cytotoxic cells only in RA-SF. On the basis of these results, an intra-articular immunomodulating treatment with thymopentin has been performed: its effects were characterized by an increase of CD8+CD11b+ T cells in the CD8 subset parallel to the enhancement of the suppressor-inducer/naive T cells in the CD4 subset with a statistically significant correlation. The enhanced levels of soluble CD8 decreased after treatment in RA-SF, whereas the soluble IL-2R levels were not significantly modified. Clinical evaluation showed a significative amelioration in all considered parameters.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832810

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  4 in total

1.  The levels of memory (CD45RA-, RO+) CD4+ and CD8+ peripheral blood T-lymphocytes correlate with IgM rheumatoid factors in rheumatoid arthritis.

Authors:  M Neidhart; K Fehr; F Pataki; B A Michel
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

2.  Expression of CD69 antigen on synovial fluid T cells in patients with rheumatoid arthritis and other chronic synovitis.

Authors:  A Afeltra; M Galeazzi; G M Ferri; A Amoroso; O De Pità; F Porzio; L Bonomo
Journal:  Ann Rheum Dis       Date:  1993-06       Impact factor: 19.103

Review 3.  Thymopentin and splenopentin as immunomodulators. Current status.

Authors:  V K Singh; S Biswas; K B Mathur; W Haq; S K Garg; S S Agarwal
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

Review 4.  Peptides: Prospects for Use in the Treatment of COVID-19.

Authors:  Vladimir Khavinson; Natalia Linkova; Anastasiia Dyatlova; Boris Kuznik; Roman Umnov
Journal:  Molecules       Date:  2020-09-24       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.